{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T15:27:11Z","timestamp":1763911631518,"version":"3.41.2"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To investigate the incidence, management, and outcomes of eyes with active uveitis and central serous chorioretinopathy (CSCR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective chart review.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 4,034 patients diagnosed with uveitis during the 8-year study period, 20 (0.5%) had comorbid active uveitis and CSCR, followed for a median of 34 months. Patients were stratified based on diagnoses sequence. In Cohort 1, four eyes (3 patients) initially diagnosed with active uveitis and later developed active CSCR at a median of 65 days after corticosteroid initiation, with resolution of CSCR occurring in all eyes at a median of 104 days after withdrawing corticosteroids. Three eyes (2 patients) developed worsening inflammation on corticosteroid withdrawal requiring corticosteroid-sparing immunosuppression. In Cohort 2, 21 eyes (17 patients) with inactive CSCR were later diagnosed with active uveitis. Fifteen eyes (12 patients) were treated with corticosteroids, and nine eyes (8 patients) developed active CSCR. The CSCR persisted after corticosteroid withdrawal in six eyes (5 patients) necessitating targeted therapy for CSCR. The other six eyes (5 patients) of Cohort 2 were observed or treated with topical NSAIDS with resolution of uveitis. All patients had inactive uveitis and CSCR at the final follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>A complex relationship exists between CSCR and uveitis. Control of both diseases is possible through the judicious use of corticosteroids, nonsteroidal immunosuppression, and therapies targeted at persistent CSCR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004478","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T17:05:40Z","timestamp":1743786340000},"page":"1527-1535","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["INCIDENCE, MANAGEMENT, AND OUTCOMES OF EYES WITH COMORBID ACTIVE UVEITIS AND CENTRAL SEROUS CHORIORETINOPATHY"],"prefix":"10.1097","volume":"45","author":[{"given":"Michael K.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bita","family":"Momenaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collin J.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saif A.","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Orlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Sivalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunir","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James P.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3899-4456","authenticated-orcid":false,"given":"Jordan D.","family":"Deaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250723","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.survophthal.2012.07.004","article-title":"Central serous chorioretinopathy: update on pathophysiology and treatment","volume":"58","author":"Nicholson","year":"2013","journal-title":"Surv Ophthalmol"},{"key":"R2-20250723","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ceo.14201","article-title":"Central serous chorioretinopathy: a review","volume":"51","author":"Fung","year":"2023","journal-title":"Clin Exp Ophthalmol"},{"key":"R3-20250723","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/bjo.81.11.962","article-title":"Endogenous cortisol profile in patients with central serous chorioretinopathy","volume":"81","author":"Garg","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"R4-20250723","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0161-6420(02)01975-9","article-title":"Endocrine abnormalities in patients with central serous chorioretinopathy","volume":"110","author":"Haimovici","year":"2003","journal-title":"Ophthalmology"},{"key":"R5-20250723","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0039-6257(02)00338-7","article-title":"Central serous chorioretinopathy and glucocorticoids","volume":"47","author":"Bouzas","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"R6-20250723","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/archopht.122.6.926","article-title":"Central serous chorioretinopathy associated with periocular corticosteroid injection treatment for HLA-B27-associated iritis","volume":"122","author":"Baumal","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R7-20250723","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/09546634.2015.1136049","article-title":"Localized topical steroid use and central serous retinopathy","volume":"27","author":"Chan","year":"2016","journal-title":"J Dermatol Treat"},{"key":"R8-20250723","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/lary.21967","article-title":"Bilateral central serous chorioretinopathy caused by intranasal corticosteroids: a case report and review of the literature","volume":"121","author":"Kleinberger","year":"2011","journal-title":"Laryngoscope"},{"key":"R9-20250723","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00417-008-0932-2","article-title":"Exacerbation of central serous chorioretinopathy following intravitreal triamcinolone injection","volume":"246","author":"Kocabora","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R10-20250723","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/0301-4738.16181","article-title":"Acute bilateral central serous chorioretinopathy following intra-articular injection of corticosteroid","volume":"53","author":"Mondal","year":"2005","journal-title":"Indian J Ophthalmol"},{"key":"R11-20250723","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4103\/0253-7613.84985","article-title":"Steroid-induced central serous retinopathy","volume":"43","author":"Shah","year":"2011","journal-title":"Indian J Pharmacol"},{"key":"R12-20250723","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R13-20250723","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"R14-20250723","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4274\/tjo.galenos.2022.96461","article-title":"Half-fluence photodynamic therapy for central serous chorioretinopathy in a patient receiving corticosteroids for Beh\u00e7et's uveitis","volume":"52","author":"\u00d6zdemir","year":"2022","journal-title":"Turk J Ophthalmol"},{"key":"R15-20250723","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/medicina59050949","article-title":"Diagnosis and treatment of central serous chorioretinopathy in patients with scleritis","volume":"59","author":"Tsai","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"R16-20250723","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3109\/09273948.2011.650776","article-title":"Central serous chorioretinopathy, corticosteroids, and uveitis","volume":"20","author":"Khairallah","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"R17-20250723","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4103\/ijo.IJO_831_18","article-title":"Clinical profile of uveitis patients developing central serous chorioretinopathy: an experience at a tertiary eye care center in India","volume":"67","author":"Majumder","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R18-20250723","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2016.05.002","article-title":"Vogt-Koyanagi-Harada disease","volume":"62","author":"O'Keefe","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"R19-20250723","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","article-title":"Immunosuppression for the uveitides","volume":"125","author":"Jabs","year":"2018","journal-title":"Ophthalmology"},{"key":"R20-20250723","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.2147\/JIR.S288294","article-title":"Topical anti-inflammatory agents for non-infectious uveitis: current treatment and perspectives","volume":"15","author":"Balasubramaniam","year":"2022","journal-title":"J Inflamm Res"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T02:00:46Z","timestamp":1753236046000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004478","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"type":"print","value":"0275-004X"},{"type":"electronic","value":"1539-2864"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}